Both methods require additional genetic manipulations of CAR-T. Here we transduce 7CAR into bulk T cells without CD7 disruption and thereafter allow CAR-T cells to emergein vitroafter fratricidal "natural selection". The biological characteristics of these naturally selected anti-CD7 CAR (NS7CAR)...
ClinicalTrials数据库提供临床试验Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances的登记号NCT04934774,试验分期Phase 1以及申办者iCell Gene Therapeutics的信息,更过关于临床试验的其他信息查询就在戊戌数据美国临床试验数据库.
Molecular expansions of CAR-T cells peaked on day 10 in peripheral blood (mean 52,150 copies/ug DNA) and persisted out to day 56. Of all pts tested (15), none developed novel anti-HLA antibodies against the donor, and no anti-drug antibodies against the CAR-construct were detected. ...
Diogo Gomes-Silvia et al., “CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies,” Blood, vol. 130, No. 3, May 24, 2017. Walter, Roland B, et al, “ITIM-dependant endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phospho...
Patients treated with allogeneic CAR-T cells had higher remission rate, less recurrence and more durable CAR-T survival than those receiving autologous products. Allogeneic CAR-T cells appeared to be a better option for patients with T-cell malignancies....
Chimeric antigen receptor (CAR) T cells have remarkable efficacy in patients with B cell acute lymphoblastic leukaemia (ALL), but have not been successful to date in patients with T cell ALL (T-ALL). Now, data from Pan and colleagues demonstrate the safety and impressive short-term efficacy ...
We demonstrate that the in vivo activation of NK cells with [poly (I:C)] in SCID mice bearing disseminated human T-cell leukaemia xenografts resulted in a significant improvement in the therapeutic activity exerted by an intact murine monoclonal antibody against human CD7. This was also seen ...
Chimeric antigen receptor T cells (CAR-T cells) have been widely used for haematologic malignancies. Current CAR-T therapies for acute myeloid leukaemia mostly target myeloid-lineage antigens, such as CD123 and CD33, which may be associated with potential haematopoietic toxicity. As a lineage-...